1. Home
  2. LOPE vs ACAD Comparison

LOPE vs ACAD Comparison

Compare LOPE & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LOPE

Grand Canyon Education Inc.

HOLD

Current Price

$152.00

Market Cap

4.5B

Sector

Real Estate

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.39

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOPE
ACAD
Founded
1949
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.8B
IPO Year
2008
2000

Fundamental Metrics

Financial Performance
Metric
LOPE
ACAD
Price
$152.00
$21.39
Analyst Decision
Buy
Buy
Analyst Count
2
22
Target Price
$220.00
$30.55
AVG Volume (30 Days)
222.7K
1.2M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
2.80
0.02
Revenue
$511,257,000.00
$726,437,000.00
Revenue This Year
$8.67
$18.80
Revenue Next Year
$6.66
$11.70
P/E Ratio
$53.82
$1,062.50
Revenue Growth
N/A
40.45
52 Week Low
$145.00
$19.69
52 Week High
$223.04
$28.35

Technical Indicators

Market Signals
Indicator
LOPE
ACAD
Relative Strength Index (RSI) 42.68 49.76
Support Level $148.07 $21.04
Resistance Level $155.20 $22.03
Average True Range (ATR) 4.12 0.59
MACD 0.27 0.05
Stochastic Oscillator 55.26 57.35

Price Performance

Historical Comparison
LOPE
ACAD

About LOPE Grand Canyon Education Inc.

Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges, both online and on the ground at its campus in Phoenix, Arizona, and at four off-site classroom andlaboratory sites. The Company generates all of its revenue through service agreements with its university partners.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: